Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19
- Country:
- India
Fulcrum Therapeutics Inc said on Wednesday it has started the late-stage trial of its experimental muscle disorder drug, losmapimod, in high-risk hospitalized adults tested positive for COVID-19.
The company expects to report topline data in the first quarter of 2021.
Fulcrum said it had exclusively in-licensed losmapimod from GlaxoSmithKline PLC last year.
Google News